What we do at the Functional Genomics Centre
We’re here to provide our research community with access to cutting-edge CRISPR technology and support researchers in designing experiments with the greatest chance of success.
Our standalone laboratory offers world-class functional genomic research capabilities to support your research. We leverage the strengths of CRUK’s scientific network and AstraZeneca’s oncology drug discovery and development experience to drive scientific innovation in how new drug targets and approaches are identified and validated.
The CRUK-AZ Functional Genomics Centre itself will be a truly collaborative environment with industry and academic scientists working side-by-side in a jointly-run facility. This unique partnership will enable UK research to perform on a world stage in the functional genomics field, generating tangible progress in our deeper understanding of cancer and new strategies to address areas of unmet need for the benefit of patients. By forming this alliance CRUK and AstraZeneca are building a UK-based critical mass of expertise in the multidisciplinary skills required to use CRISPR and other gene editing technologies in translational oncology research.
We’re Europe’s largest independent funder of cancer research. With more than 100 years of history, we have a strong track record of funding breakthrough discovery science, including seven Nobel Prize winners.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
While we work with AstraZeneca to share resource and expertise within the centre, projects run by CRUK and arising data associated to these projects are kept separate from those brought into the Centre by AstraZeneca. Your projects and arising data will remain unencumbered when entering the centre.
If you think your research could benefit from access to novel, state-of-the art, CRISPR technology we’d love to work with you to progress your research. With support from our expert team, we can help you plan your project to give you the best opportunity for success.